Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Summary

Adding chemotherapy or anti-VEGF to immunotherapy is an emerging strategy to enhance the efficacy of immunotherapy in many cancers. This phase 2 study aims to explore the preliminary efficacy of combination pembrolizumab with lenvatinib and chemotherapy in NSCLC patients with sensitizing EGFR, ALK, or ROS1 genetic aberration refractory to standard targeted therapy.

Timeline

Start

2021-10-05

Primary completion

2024-08

Completion

2024-12

Publications

• Chan HW, Tse CCL, Li YC, Leung R, Kwok GW, Wong JSL, Li KH, Tsang JWY, Li CW, Lo JWY, Tang V, Hui R, Yau T, Ho JCM, Chiu JWY. A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic non-small cell lung cancer harbouring targetable genomic alterations who progressed on standard tyrosine kinase inhibitors. Invest New Drugs. 2025 Dec;43(6):1191-1200. doi: 10.1007/s10637-025-01589-6. Epub 2025 Nov 10.

Drugs

Indications